Pharma Stocks

Gland Pharma Share: The market price of Gland Pharma hit a high of ₹2,989.2 in intra-day deals on Tuesday. The stock bounced back 90 per cent from its 52-week low of ₹1,575 touched on March 16, 2026.

In the past month, Laurus Labs outperformed the market by surging 22 per cent, as compared to 2.1 per cent rise in the Nifty Midcap 50 index.

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

As the largest pure-play API/CDMO, Divi's should continue benefiting from custom-synthesis order-book conversion and the structural China+1/BIOSECURE-linked tailwind, analysts believe.

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

Dr Reddys Laboratories stock hit a fresh 52-week high of ₹1,410 in Monday's intra-day trade, backed by strong surge in trading volume.

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.